U.S. Markets closed

DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019

NEW YORK, NY / ACCESSWIRE / July 5, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nabriva Therapeutics PLC ("Nabriva" or the "Company") (NBRV) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nabriva securities between November 1, 2018 and April 30, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/nbrv.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

On April 30, 2019, Nabriva disclosed receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") for the Company's New Drug Application ("NDA") seeking marketing approval of CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva advised investors that "[t]he CRL requests that Nabriva address issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers prior to the FDA approving the NDA."

On this news, Nabriva's stock price fell $0.82 per share, or 27.42%, to close at $2.17 per share on May 1, 2019.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/nbrv or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Nabriva you have until July 8, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/550417/DEADLINE-ALERT--NBRV-Nabriva-Therapeutics-PLC-Bronstein-Gewirtz-Grossman-LLC-Reminds-Shareholders-with-Losses-Exceeding-50K-of-Class-Action-and-Lead-Plaintiff-Deadline-July-8-2019